[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"encephalopathy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:encephalopathy":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,45,90,118,147,176,209,236,267,294],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":4,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100513897","healthy-little-eyes-100513897",false,"NCT05971446","Healthy Little Eyes","Visual Function as a Novel Outcome Measure Following Neonatal Hypoxic Ischemic Encephalopathy","HIE Neonate Inclusion Criteria:\n\n* Inpatient Neonates diagnosed with HIE\n* Pediatric patients who are less than 78 hours of age at the time of enrollment\n* Participants whose parent\u002Flegal guardian is able to complete consenting process in English\n\nHIE Neonate Exclusion Criteria:\n\n* Participants with prenatally diagnosed or congenital brain and\u002For eye abnormalities not associated with HIE, including but not limited to microphthalmia, anophthalmia, congenital cataract, eye or eyelid coloboma, congenital glaucoma, CMV retinitis, optic nerve hypoplasia, aniridia, cryptophthalmos, globe abnormalities\n* Participants who have a known central nervous system illness other than HIE, including but not limited to congenital brain malformations or congenital hydrocephalus\n* Participants whose parent\u002Flegal guardian is unable to provide informed consent, including participants who are in foster care, participants within state custody, and participants of minor parents\n\nWaisman, AFCH NBFU, or CERU Clinic HIE Patient Inclusion Criteria:\n\n* Pediatric patients who have a diagnosis of HIE and present to the Newborn Follow Up Clinic\n* Pediatric patients who are less than 36 months of age at the time of enrollment\n* Participants whose parent\u002Flegal guardian is able to complete consenting process in English\n\nWaisman, AFCH NBFU, or CERU Clinic HIE Patient Exclusion Criteria:\n\n* Participants with prenatally diagnosed or congenital brain and\u002For eye abnormalities not associated with HIE, including but not limited to microphthalmia, anophthalmia, congenital cataract, eye or eyelid coloboma, congenital glaucoma, CMV retinitis, optic nerve hypoplasia, aniridia, cryptophthalmos, globe abnormalities\n* Participants who have a known central nervous system illness not associated with HIE and its complications. Complications may include seizures, hydrocephalus, and stroke, which are NOT exclusionary. Examples of exclusionary conditions include but are not limited to traumatic brain injury outside the perinatal period, meningitis, or diagnosis of brain tumor\n* Participants whose parent\u002Flegal guardian is unable to provide informed consent, including participants who are in foster care, participants within state custody, and participants of minor parents\n\nWell Baby Inclusion Criteria:\n\n* Patient in Meriter's Newborn Nursery\n* ≥37 and \\\u003C42 weeks gestational age\n* 5-minute Apgar Score ≥7\n* Occipital Frontal Circumference (OFC) is within average limits for age (\\\u003C97th percentile and \\>3rd percentile)\n\nWell Baby Exclusion Criteria:\n\n* Admitted to the NICU for any reason\n* Known genetic abnormality\n* Diagnosed with HIE\n* Diagnosed with Hypoglycemia\n* Diagnosed with Hyperbilirubinemia requiring phototherapy\n* Identified prenatal exposure to substances, including illicit drugs, alcohol, and\u002For tobacco\n* Known or suspected neonatal infection requiring treatment (e.g., antibiotics)\n* TORCH infections\n* Abnormal newborn hearing screen\n* Abnormal toxicology screening\n* Identified as large for gestational age (LGA) or small for gestational age (SGA)\n* Participants with prenatally diagnosed or congenital eye abnormalities, including but not limited to microphthalmia, anophthalmia, congenital cataract, eye or eyelid coloboma, congenital glaucoma, CMV retinitis, optic nerve hypoplasia, aniridia, cryptophthalmos, globe abnormalities, and nystagmus\n* Subjects who have a known central nervous system illness or malformation, including but not limited to congenital brain malformations or congenital hydrocephalus\n* Participants whose parent\u002Flegal guardian is unable to provide informed consent, including subjects who are in foster care, subjects within state custody, and subjects of minor parents\n* The attending medical team does not approve",true,"ALL","36 Months",{"count":20,"type":21},125,"ESTIMATED","OBSERVATIONAL","The purpose of this research study is to gather more information on how eye injury is related to a baby's future development and see if eye function and brain test results can be used, along with current measures, to better diagnose and treat babies with hypoxic-ischemic encephalopathy (HIE).\n\nParticipants will undergo up to two eye exam sessions, involving both Visual Evoked Potential (VEP) and Electroretinogram (ERG) exams.",[25,26,27],"Hypoxic-Ischemic Encephalopathy","Neonatal Encephalopathy","Encephalopathy",[29,30,31],"neonatal","visual evoked potential","electroretinogram","RECRUITING","2026-05-12",{"date":35,"type":36},"2026-05-14","ACTUAL",{"date":38,"type":36},"2020-02-24",{"date":40,"type":21},"2029-07",{"name":42,"class":43},"University of Wisconsin, Madison","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":17,"minAge":52,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":55,"conditions":56,"keywords":62,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":44},"100637552","prospective-observational-multimodal-neuromonitoring-in-adult-nsicu-patients-100637552","NCT07577713","Prospective Observational Multimodal Neuromonitoring in Adult NSICU Patients","Prospective Observational Multimodal Neuromonitoring in Adult Neurosciences Intensive Care Unit Patients: Characterization of Noninvasive Cerebral Autoregulation Indices, Quantitative EEG, and Physiologic Correlates Across NSICU Diagnoses","Inclusion Criteria:\n\n* Age 18 years or older\n* Admitted to the NSICU at UT Southwestern Medical Center\n* Informed consent obtained from subject or legally authorized representative (as defined under Texas Health and Safety Code Section 166.039), or consent process underway per institutional policy\n* At least one study monitoring modality feasible (SedLine qEEG and\u002For Brain4Care extensometry); NIRS data collected where already in standard clinical use\n\nExclusion Criteria:\n\n* Age younger than 18 years\n* Prisoner status\n* Active declination of participation by subject or legally authorized representative\n* Absence of both subject and legally authorized representative consent when required\n* Clinical condition preventing safe placement of any study monitor (e.g., extensive facial or scalp injury, surgical dressings or hardware at all possible sensor sites, open wounds at sensor locations, severe uncontrolled agitation)\n* Anticipated clinical data capture insufficient for meaningful analysis\n* Urgent clinical priorities making research monitor placement inappropriate at time of approach\n* Inability to provide informed consent in English; study consent materials are available in English only","18 Years",{"count":54,"type":21},300,"This is a prospective observational cohort study of adult patients admitted to the Neurosciences Intensive Care Unit (NSICU) at UT Southwestern Medical Center. The study acquires multimodal neuromonitoring data - including SedLine quantitative EEG (qEEG) from standard-of-care monitoring, Brain4Care (B4C) noninvasive intracranial dynamics monitoring, and near-infrared spectroscopy (NIRS)-derived cerebral autoregulation (CA) indices where NIRS is already in clinical use - and links these data to bedside physiologic, medication, diagnostic, and clinical outcome variables during standard care. No alteration of clinical management occurs. The study prioritizes aneurysmal subarachnoid hemorrhage (aSAH) patients to characterize the natural history of noninvasive CA parameter evolution through the delayed cerebral ischemia (DCI) window (admission through Day 14) and provides preliminary data for subsequent interventional study design.",[57,58,59,60,61,27],"Subarachnoid Hemorrhage, Aneurysmal","Brain Injuries, Traumatic","Cerebral Hemorrhage","Ischemic Stroke","Delayed Emergence From Anesthesia",[63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79],"aneurysmal subarachnoid hemorrhage","delayed cerebral ischemia","cerebral autoregulation","CPPopt","MAPopt","Brain4Care","SedLine","quantitative EEG","near-infrared spectroscopy","COx","TOxA","transcranial Doppler","neurocritical care","NSICU","noninvasive intracranial monitoring","Moberg Clinical Platform","multimodal neuromonitoring","NOT_YET_RECRUITING","2026-05-04",{"date":83,"type":36},"2026-05-11",{"date":85,"type":21},"2026-07",{"date":87,"type":21},"2029-09",{"name":89,"class":43},"University of Texas Southwestern Medical Center",{"id":91,"slug":92,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":94,"acronym":95,"eligibilityCriteria":96,"healthyVolunteers":11,"sex":17,"minAge":97,"maxAge":98,"enrollmentInfo":99,"targetDuration":4,"studyType":101,"phases":102,"briefSummary":104,"conditions":105,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":117},"100607592","against-chikungunya-virus-and-neonatal-infection-100607592","NCT07190560","Against Chikungunya Virus and Neonatal Infection","ConvictionCHIK","Inclusion Criteria:\n\n* Treatment group\n\nNewborn:\n\n* whose mother has a clinical and\u002For laboratory diagnosis of Chikungunya (CHIK) infection occurring between 2 days before and 2 days after birth.\n* Hospitalized in a Level III neonatology unit in Mayotte or at the University Hospital of La Réunion.\n* Eligible for experimental treatment (called PC-CHIK-V):\n\n  * If the maternal infection was diagnosed between2 days before and the day of delivery, treatment can be administered within the first 12 hours of the newborn's life.\n  * If the maternal infection was diagnosed between 1 day and 2 days after birth, treatment can be administered within 12 hours of diagnosis.\n* Whose holders of parental authority have given free, informed, and written consent prior to any examination required for the research. Parallel Cohort of\n\nUntreated Newborns (parallel observational cohort)\n\nNewborns:\n\n* Whose mother has a clinical and\u002For laboratory diagnosis of CHIK-V infection occurring between 2 days before and 2 days after birth.\n* Hospitalized in a Level III neonatology unit in Mayotte or at the University Hospital of La Réunion.\n* Not treated with PC-CHIK-V:\n* Monitored in one of the units of the Neonatology Department for at least 5 days from the day of birth.\n* Whose holders of parental authority (or the holder if the mother is the sole holder of parental authority) have been informed of the research and have not objected to the use of data collected during hospitalization for research purposes.\n\nExclusion Criteria:\n\n* Newborns who present at birth with clinical criteria for ahypoxic-ischemic encephalopathy (HIE) that require therapeutic hypothermia according to the national protocol for \"neonatal therapeutic hypothermia\"\n* Newborns who require phototherapy treatment at the time of enrollment using devices with a maximum energy wavelength less than 425 nm and\u002For with an emission bandwidth with a lower limit of \\\u003C375 nm.","0 Days","2 Days",{"count":100,"type":21},60,"INTERVENTIONAL",[103],"NA","The goal of this clinical trial is to learn if administration of plasma, from a whole blood donation from an individual who has declared a Chikungunya infection for less than 6 months , to a newborn, whose mother has a peripartum chikungunya infection, will have an impact on the proportion of newborns surviving without encephalitis\u002Fencephalopathy (EE) within the first 5 days of life. Researchers will compare results to an observational study of 30 newborns who couldn't have been proposed to participate at the clinical trial, because of delay of diagnosis or delay of transfer to hospital which doesn't allow transfusion or parents not accepting plasma transfusion to the newborn.\n\nParticipants of the clinical trial will:\n\n* receive a transfusion,\n* visit the clinic and undergo biological tests every day until day 7 and once between 1 and 3 months.\n\nParticipant of observational study as part of their regular medical care, and biological data will be reused for the research from the mother's diagnosis until the newborn reaches 3 months of age",[106,107,108,27],"Chikungunya Virus Infection","Neonatal","Transfusion",{"date":110,"type":36},"2026-05-08",{"date":112,"type":21},"2026-08-01",{"date":114,"type":21},"2027-12-01",{"name":116,"class":43},"Centre Hospitalier Universitaire de la Réunion",2,{"id":119,"slug":120,"hasResults":11,"nctId":121,"briefTitle":122,"officialTitle":123,"acronym":124,"eligibilityCriteria":125,"healthyVolunteers":11,"sex":17,"minAge":126,"maxAge":52,"enrollmentInfo":127,"targetDuration":129,"studyType":22,"phases":4,"briefSummary":130,"conditions":131,"keywords":134,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":4},"100634476","the-aim-of-the-present-study-is-to-determine-outcome-predictors-in-children-who-were-diagnosed-as-acute-disseminated-encephalomyelitis-adem-100634476","NCT07540182","The Aim of the Present Study is to Determine Outcome Predictors in Children Who Were Diagnosed as Acute Disseminated Encephalomyelitis (ADEM).","Outcome Predictors in Children With Acute Disseminated Encephalomyelitis at Assuit University Children Hospital","ADEM disease","Inclusion Criteria:\n\n* Children aged from 6 months old to 18 years.\n* Presence of clinical signs of acute encephalopathy with multifocal neurological deficits.\n* MRI findings suggestive of demyelinating lesions.\n\nExclusion Criteria:\n\n* Pediatric patients diagnosed who were as multiple sclerosis.\n* Pediatric patients with clinical signs and radiological findings suggestive of neuromyelitis optica spectrum disorder.\n* Pediatric patients with infectious encephalitis.\n* Pediatric patients with metabolic or genetic neurological disorders","6 Months",{"count":128,"type":21},25,"25 Months","The aim of the present study is to determine outcome predictors in children who were diagnosed as acute disseminated encephalomyelitis (ADEM).",[132,133,27],"Acute Disseminated Encephalomyelitis","Encephalomyelitis",[135,136,137],"ADEM","Pediatric Encephalomyelitis","Demyelinating Disorders","2026-04-17",{"date":140,"type":36},"2026-04-20",{"date":142,"type":21},"2026-03-29",{"date":144,"type":21},"2027-04",{"name":146,"class":43},"Assiut University",{"id":148,"slug":149,"hasResults":11,"nctId":150,"briefTitle":151,"officialTitle":152,"acronym":153,"eligibilityCriteria":154,"healthyVolunteers":11,"sex":17,"minAge":155,"maxAge":4,"enrollmentInfo":156,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":158,"conditions":159,"keywords":162,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":44},"100529339","automating-delirium-severity-in-the-icu-100529339","NCT06172491","Automating Delirium Severity in the ICU","Harnessing the Power of Technology to Transform Delirium Severity Measurement in the ICU","ADS-ICU","Inclusion Criteria: • Age \\>50;\n\n* Estimated length of stay \\>24 hours in ICU; and\n* Are not admitted for acute alcohol intoxication, drug (prescribed or illicit) overdose or withdrawal.\n\nExclusion Criteria:\n\n* Admitted for acute alcohol intoxication, drug (prescribed or illicit) overdose or withdrawal.\n* Admitted for acute neuronal injury\n* Unable to communicate with research team due to sensory deficits (aphasic, blind, deaf) or language (does not speak English)","50 Years",{"count":157,"type":21},400,"The goal of this observational study is to develop a passive digital marker (PDM) for delirium severity and examine its performance in comparison to validated delirium severity tools in ICU patients \\>50 years of age.\n\nThe main questions it aims to answer are:\n\n* Is the trained convolutional neural network able to reliably measure delirium severity.\n* Is the Passive Digital Marker able to accurately measure delirium severity\n* Is the Passive Digital Marker acceptable and usable by frontline ICU nurse clinicians, patients, and their identified proxies (i.e., caregivers).\n\nParticipants will:\n\n* Study participation involves a video camera recording you 24 hours per day while you are a patient in the Intensive Care Unit (ICU).\n* Study staff will visit you 4 times each day you are in the ICU. You will be asked questions each time they visit to train the digital marker and see differences between assessments and camera data.",[160,27,161],"Intensive Care Unit Delirium","Delirium",[161,163,164,165,166],"Severity","Digital marker","Computer Vision","Artificial Intelligence","2026-04-02",{"date":169,"type":36},"2026-04-08",{"date":171,"type":36},"2023-01-15",{"date":173,"type":21},"2028-05-31",{"name":175,"class":43},"Mayo Clinic",{"id":177,"slug":178,"hasResults":11,"nctId":179,"briefTitle":180,"officialTitle":181,"acronym":182,"eligibilityCriteria":183,"healthyVolunteers":11,"sex":17,"minAge":52,"maxAge":4,"enrollmentInfo":184,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":186,"conditions":187,"keywords":196,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":198,"lastUpdatePostDateStruct":199,"startDateStruct":201,"completionDateStruct":203,"leadSponsor":205,"locationsCount":208},"100544420","comind-early-feasibility-study-100544420","NCT06368648","CoMind Early Feasibility Study","An Early Feasibility Study for the Development of a Model to Non-Invasively Estimate Intracranial Pressure (ICP) and New Metrics of Cerebral Autoregulation (CAR) Using the CoMind One EFS Device","CoMind EFS","Inclusion Criteria:\n\n1. Male or female sex at birth, and aged 18 years or older on the date of enrollment.\n2. Receiving continuous invasive ICP monitoring (Bolt or EVD) as part of standard care.\n3. Invasive ICP monitor catheter penetrating the parenchyma or ventricles.\n4. Receiving continuous invasive ABP monitoring as part of standard care.\n\nExclusion Criteria:\n\n1. Presence of any implant (cosmetic or otherwise) in the frontal bone in such proximity to the CoMind One EFS Sensor that they might physically touch.\n2. Open wounds on the forehead such that CoMind One EFS Sensor cannot be safely placed over an area of intact skin\n3. Presenting with radiographic evidence of a non-intact skull at the recording site on admission.\n4. If patient is enrolled in an intervention\u002Fstudy that may interfere with SoC ICP measurements or the CoMind One EFS device measurement then the patient is ineligible.\n5. Patients with decompressive craniectomy will be excluded unless a CoMind One EFS recording can be made from intact skull.",{"count":185,"type":21},581,"The purpose of this research, which has been determined as non-significant risk by the central IRB overseeing the study, is to obtain information to help further develop a machine (a medical device) to measure the pressure around the brain from the outside (this pressure is called intracranial pressure or ICP). Monitoring and managing ICP is an important part of care for patients with conditions such as Traumatic Brain Injury (TBI). However, the current way of measuring ICP requires surgery to drill a hole into the skull, and therefore can introduce additional risks such as infections and pain.\n\nRecent research has shown it may be possible to measure ICP without needing surgery. This technology is in development, but large amounts of data is required to build these new devices.\n\nThrough collecting a large database of information from patients who have both the routine surgical device and the research device applied to their head, the research team will work to develop and test an effective and potentially safer way of monitoring patient ICP.",[188,189,190,191,192,27,193,194,195],"Intracranial Pressure","Intracranial Pressure Changes","Traumatic Brain Injury","Intracerebral Hemorrhage","Encephalitis","Hydrocephalus","Stroke","Autoregulation",[188,190,197],"Cerebral Autoregulation","2026-02-12",{"date":200,"type":36},"2026-02-13",{"date":202,"type":36},"2024-11-27",{"date":204,"type":21},"2026-11",{"name":206,"class":207},"CoMind Technologies Limited","INDUSTRY",14,{"id":210,"slug":211,"hasResults":11,"nctId":212,"briefTitle":213,"officialTitle":213,"acronym":4,"eligibilityCriteria":214,"healthyVolunteers":11,"sex":17,"minAge":215,"maxAge":216,"enrollmentInfo":217,"targetDuration":4,"studyType":101,"phases":219,"briefSummary":220,"conditions":221,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":226,"lastUpdatePostDateStruct":227,"startDateStruct":229,"completionDateStruct":231,"leadSponsor":233,"locationsCount":235},"100610030","clinical-trial-protocol-alzheimers-dementia-underlying-encephalopathy-100610030","NCT07222280","Clinical Trial Protocol: Alzheimer's Dementia Underlying Encephalopathy","Inclusion Criteria:\n\n* Ages 60 to 90 years old\n* No prior diagnosis of dementia\n* Currently hospitalized with cognitive diagnosis, including but no limited to; delirium, encephalopathy, etc. thought to be secondary to a toxic\u002Fmetabolic state\n\nExclusion Criteria:\n\n* Age under 60 years\n* Prior diagnosis of dementing illness or other organic etiology to cognitive impairment","60 Years","90 Years",{"count":218,"type":21},30,[103],"The goal of this clinical trial is to determine if utilizing the Quest AD-Detect blood test, while patient's are hospitalized for a cognitive diagnosis (such as delirium or encephalopathy), will result in an earlier diagnosis of underlying Alzheimer's disease.\n\n* Will this blood test have the ability to distinguish between Alzheimer's disease and other causes of cognitive impairment in the inpatient setting?\n* Neurology Clinic will complete a 6-month post-hospitalization follow up with patients who have had the Quest AD-Detect Alzheimer's Disease blood test completed while they were inpatient to discuss the risk assessment portfolio",[222,223,224,27,225],"Alzheimer Dementia","Alzheimer Disease","Delirium Confusional State","Cognitive Abnormality","2025-10-27",{"date":228,"type":36},"2025-10-29",{"date":230,"type":36},"2025-06-10",{"date":232,"type":21},"2026-03-31",{"name":234,"class":43},"Covenant Health, US",6,{"id":237,"slug":238,"hasResults":11,"nctId":239,"briefTitle":240,"officialTitle":241,"acronym":4,"eligibilityCriteria":242,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":243,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":244,"conditions":245,"keywords":253,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":258,"lastUpdatePostDateStruct":259,"startDateStruct":261,"completionDateStruct":263,"leadSponsor":265,"locationsCount":117},"100589740","neuroimmunology-registry-and-biobank-100589740","NCT06958341","Neuroimmunology Registry and Biobank","Registry for Patients With Antibody-mediated Neuroimmunological Diseases","Inclusion Criteria:\n\n1. Differential diagnosis: suspected neuroimmunological disease in which a lumbar puncture is indicated for further diagnosis and treatment decision\n2. Individuals with unclear clinical diagnosis where additional CSF is to be collected for isolation of B cells and production of monoclonal antibodies. The clinical condition of the patients and his\u002Fher compliance have to allow an extra 2-3 ml of CSF to be collected.\n3. Age: all age groups\n4. Gender: patients of both sexes will be included\n\nExclusion criteria:\n\n\\[1\\] Withdrawal of consent",{"count":54,"type":21},"A variety of antineuronal antibodies have been detected in the cerebrospinal fluid (CSF) of patients with neurological diseases. This raises the question of whether these antibodies are disease-specific or merely an epiphenomenon of inflammatory processes in the brain.\n\nThe registry was established with the following objectives: \\[1\\] Are antineuronal antibodies much more common than previously thought in various neurological disorders for which the etiology has not yet been elucidated? \\[2\\] Can further correlations, such as those between HSV infection and NMDA receptor autoimmunity, be identified? \\[3\\] Are these antibodies mainly non-specific epiphenomena or are they crucial for the pathogenesis? \\[4\\] What is the clinical course of patients with antineuronal antibodies and their response to therapy? These questions will be addressed in a broad immunohistological screening of a large number of CSF samples and a clinical database of patients with neurological disorders.",[27,246,247,248,249,250,251,252],"Psychosis","Impaired Consciousness","Epilepsy","Movement Disorders","Motor Neuropathy","Spasticity","Ataxia",[254,255,256,257],"neuroimmunological diseases","cerebrospinal fluid","cell-based assay","tissue-based assay","2025-05-03",{"date":260,"type":36},"2025-05-06",{"date":262,"type":36},"2021-02-01",{"date":264,"type":21},"2031-07-01",{"name":266,"class":43},"Charite University, Berlin, Germany",{"id":268,"slug":269,"hasResults":11,"nctId":270,"briefTitle":271,"officialTitle":272,"acronym":273,"eligibilityCriteria":274,"healthyVolunteers":11,"sex":17,"minAge":275,"maxAge":276,"enrollmentInfo":277,"targetDuration":4,"studyType":101,"phases":279,"briefSummary":281,"conditions":282,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":285,"lastUpdatePostDateStruct":286,"startDateStruct":288,"completionDateStruct":290,"leadSponsor":292,"locationsCount":5},"100469621","phase-3-erythropoietin-for-neonatal-encephalopathy-in-lmic-embrace-trial-100469621","NCT05395195","Erythropoietin for Neonatal Encephalopathy in LMIC (EMBRACE Trial)","Erythropoietin Monotherapy for Brain Regeneration in Neonatal Encephalopathy in Low and Middle-Income Countries","EMBRACE","Inclusion Criteria (all of below should be met)\n\n* Inborn babies born at a gestational age greater than or equal to 36 weeks, with a birth weight \\>=1.8 kg\n* At least one of the following: need for continued resuscitation at 5 minutes of age; 5-minute Apgar score \\\u003C 6; metabolic acidosis (pH \\\u003C 7.0; base deficit \\> 16 mmol\u002FL) in cord or blood gas within the first hour of birth.\n* Moderate or severe neonatal encephalopathy on modified Sarnat staging performed between 1 to 6 hours after birth.\n\nExclusion Criteria:\n\n* Imminent death at the time of recruitment\n* Babies born at home or those admitted after 6 hours of birth.\n* Major life-threatening congenital malformations\n* Head circumference \\\u003C30 cm at birth\n* Babies undergoing induced hypothermia\n* Migrant family or parents unable\u002Funlikely to come back for follow-up at 18 months\n* Sentinel event and encephalopathy occurred only after birth\n* Unable to consent in primary language of parent(s)","1 Hour","6 Hours",{"count":278,"type":21},504,[280],"PHASE3","One million babies die, and at least 2 million survive with lifelong disabilities following neonatal encephalopathy (NE) in low and middle-income countries (LMICs), every year. Cooling therapy in the context of modern tertiary intensive care improves outcome after NE in high-income countries. However, the uptake and applicability of cooling therapy in LMICs is poor, due to the lack of intensive care and transport facilities to initiate and administer the treatment within the six-hours window after birth as well as the absence of safety and efficacy data on hypothermia for moderate or severe NE.\n\nErythropoietin (Epo) is a promising neuroprotectant with both acute effects (anti-inflammatory, anti-excitotoxic, antioxidant, and antiapoptotic) and regenerative effects (neurogenesis, angiogenesis, and oligodendrogenesis),which are essential for the repair of injury and normal neurodevelopment when used as a mono therapy in pre-clinical models (i.e without adjunct hypothermia).\n\nThe preclinical data on combined use of Eythropoeitin and hypothermia is less convincing as the mechanisms overlap. Thus, the HEAL (High dose erythropoietin for asphyxia and encephalopathy) trial, a large phase III clinical trial involving 500 babies with with encephalopathy reported that that Erythropoietin along with hypothermia is not beneficial.\n\nIn contrast, the pooled data from 5 small randomized clinical trials (RCTs) (n=348 babies), suggests that Epo (without cooling therapy) reduce the risk of death or disability at 3 months or more after NE (Risk Ratio 0.62 (95% CI 0.40 to 0.98). Hence, a definitive trial (phase III) for rigorous evaluation of the safety and efficacy of Epo monotherapy in LMIC is now warranted.",[27,283,284],"Erythropoietin","Newborn Asphyxia","2024-03-18",{"date":287,"type":36},"2024-03-19",{"date":289,"type":36},"2022-12-31",{"date":291,"type":21},"2026-12-01",{"name":293,"class":43},"Imperial College London",{"id":295,"slug":296,"hasResults":11,"nctId":297,"briefTitle":298,"officialTitle":299,"acronym":300,"eligibilityCriteria":301,"healthyVolunteers":11,"sex":17,"minAge":302,"maxAge":4,"enrollmentInfo":303,"targetDuration":305,"studyType":22,"phases":4,"briefSummary":306,"conditions":307,"keywords":312,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":316,"lastUpdatePostDateStruct":317,"startDateStruct":319,"completionDateStruct":321,"leadSponsor":323,"locationsCount":44},"100421450","cirrhosis-registry-of-hospitalized-patients-100421450","NCT04767945","Cirrhosis Registry of Hospitalized Patients","Registry of Adult Consenting Patients Admitted to the Liver Unit With Liver Cirrhosis","RH7","Inclusion Criteria:\n\n* liver cirrhosis (primarily on clinical grounds)\n* decompensating event leading to hospital admission\n* informed consent\n\nExclusion Criteria:\n\n* declined consent","19 Years",{"count":304,"type":21},2000,"15 Years","Cirrhosis registry of consecutive adult consenting patients hospitalized with liver cirrhosis in the tertiary liver unit",[308,309,310,27,311],"Cirrhosis, Liver","Frailty","Ascites","Infection",[313,314,315],"Cirrhosis","decompensation","frailty","2022-08-02",{"date":318,"type":36},"2022-08-03",{"date":320,"type":36},"2014-07-01",{"date":322,"type":21},"2029-12-31",{"name":324,"class":43},"F.D. Roosevelt Teaching Hospital with Policlinic Banska Bystrica"]